Related references
Note: Only part of the references are listed.The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice
C. Trierweiler et al.
CELL DEATH AND DIFFERENTIATION (2016)
Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy
R. Mandal et al.
ONCOGENE (2016)
17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling
Seulki Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
APASL consensus statements and recommendation on treatment of hepatitis C
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2016)
C-Jun N-terminal kinase signalling pathway in response to cisplatin
Dong Yan et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
Possible Involvement of Hepatitis B Virus Infection of Hepatocytes in the Attenuation of Apoptosis in Hepatic Stellate Cells
Reina Sasaki et al.
PLOS ONE (2016)
Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development
Juan Wang et al.
TARGETED ONCOLOGY (2016)
Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence
Wei Chen et al.
SCIENTIFIC REPORTS (2016)
Association between hepatitis B virus and MHC class I polypeptide-related chain A in human hepatocytes derived from human-mouse chimeric mouse liver
Reina Sasaki et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
Jiang Chen et al.
CANCER LETTERS (2015)
Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling
Xin Yin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Perspectives and control of hepatitis B virus infection in Taiwan
Chih-Lin Lin et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2015)
MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603
Liza C. Villaruz et al.
CLINICAL EPIGENETICS (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib
Kai Mao et al.
CANCER LETTERS (2014)
Involvement of androgen receptor and glucose-regulated protein 78 KDa in human hepatocarcinogenesis
Xia Jiang et al.
EXPERIMENTAL CELL RESEARCH (2014)
Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK
Harina Vin et al.
MOLECULAR CANCER THERAPEUTICS (2014)
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
Tokuzo Arao et al.
HEPATOLOGY (2013)
B-crystallin complexes with 14-3-3 to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
Xiao-Yong Huang et al.
HEPATOLOGY (2013)
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update
Angela Gauthier et al.
HEPATOLOGY RESEARCH (2013)
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
A. J. Zurita et al.
ANNALS OF ONCOLOGY (2012)
Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
S. Hagiwara et al.
BRITISH JOURNAL OF CANCER (2012)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial
Ann-Lii Cheng et al.
EUROPEAN JOURNAL OF CANCER (2012)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients
Michel Tod et al.
PHARMACEUTICAL RESEARCH (2011)
Induction of DNA Damage-Inducible Gene GADD45β Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells
Da-Liang Ou et al.
CANCER RESEARCH (2010)
A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer
Joline S. W. Lind et al.
CLINICAL CANCER RESEARCH (2010)
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Kandice R. Levental et al.
CELL (2009)
Molecular targeted therapy for hepatocellular carcinoma
Melanie Thomas
JOURNAL OF GASTROENTEROLOGY (2009)
TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies
Bruno Christian Koehler et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics
C Lathia et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in hepatocellular carcinoma
LL Guo et al.
LIFE SCIENCES (2005)
Effects of NF-KB oligonucleotide decoys on gene expression in P7 rat hippocampus after hypoxia/ischemia
JX Qiu et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2004)
Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA
T Kanda et al.
JOURNAL OF VIRAL HEPATITIS (2004)
Share Paper
